Consequently, NEDD1 could serve as a promising new therapeutic target for LUAD, providing an emerging treatment avenue by directly inducing cancer cell death or increasing the sensitivity of LUAD to immune checkpoint inhibitors and CAR-T cell therapies. Here, NEDD1 is linked to cancer.